Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PORTERS FIVES FORCES
6 PESTEL ANALYSIS
7 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: REGULATIONS
7.1 REGULATION IN THE U.S.
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASED INCIDENCE OF CHRONIC DISEASES
8.1.2 SURGE IN AWARENESS ABOUT THE TIMELY DIAGNOSIS OF THE DISEASE
8.1.3 INCREASED IMPLEMENTATION OF FLUOROSPOT ASSAY
8.1.4 USE OF KITS FOR VACCINE RESEARCH TO OVERCOME THE DRUG RESISTANCE
8.1.5 USE OF ELISPOT AND FLUOROSPOT ASSAY FOR CLINICAL TRIALS
8.2 RESTRAINTS
8.2.1 RISE IN COST OF THE ELISPOT AND FLUOROSPOT DETECTION KITS
8.2.2 AVAILABILITY OF ALTERNATE DETECTION KITS
8.2.3 LESS AVAILABILITY OF HIGH-QUALITY DETECTION REAGENTS
8.2.4 COMPLEXITY IN ELISPOT AND FLUOROSPOT ASSAY
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
8.3.2 RISING NUMBER OF IN-VITRO DIAGNOSTIC TESTS
8.3.3 RISING HEALTHCARE EXPENDITURE
8.3.4 INCREASING RESEARCH AND DEVELOPMENT
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
8.4.3 RISING COMPETITION BETWEEN MARKET PLAYERS
9 IMPACT OF COVID-19 ON THE NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS BY MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 ASSAY KIT
10.2.1 T-CELL ASSAY
10.2.2 B-CELL ASSAY
10.3 SUPPLEMENTARY/ANCILLARY PRODUCTS
10.4 ANALYZERS
11 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY SOURCE
11.1 OVERVIEW
11.2 HUMAN
11.3 MOUSE
11.4 MONKEY
11.5 OTHERS
12 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE
12.1 OVERVIEW
12.2 INFECTIOUS DISEASE
12.2.1 INFLUENZA
12.2.2 HIV
12.2.3 COVID-19
12.2.4 OTHERS
12.3 CANCER
12.4 AUTOIMMUNE DISEASE
12.5 ALLERGY
12.6 OTHER
13 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 DIAGNOSTIC APPLICATION
13.2.1 INFECTIOUS DISEASES
13.2.2 TRANSPLANTS
13.2.3 OTHERS
13.3 RESEARCH APPLICATION
13.3.1 CLINICAL TRIALS
13.3.2 CANCER RESEARCH
13.3.3 VACCINE DEVELOPMENT
13.3.4 OTHERS
14 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS & CLINICAL LABORATORIES
14.3 RESEARCH INSTITUTES
14.4 BIOPHARMACEUTICAL COMPANIES
14.5 OTHERS
15 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.3 DIRECT TENDER
16 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: COMPANY LANDSCAPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BD
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 OXFORD IMMUNOTEC USA, INC. (A SUBSIDIARY OF PERKINELMER INC.)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENTS
19.3 R&D SYSTEMS, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENTS
19.4 MABTECH
19.4.1 COMPANY SNAPSHOT
19.4.2 PRODUCT PORTFOLIO
19.4.3 RECENT DEVELOPMENTS
19.5 THERMO FISHER SCIENTIFIC INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ABCAM PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 CELLCARTA
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 CELLULAR TECHNOLOGY LIMITED (CTL)
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 COVANCE INC. (A SUBSIDIARY OF LABCORP DRUG DEVELOPMENT)
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 DIACLONE SAS
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 MIKROGEN GMBH
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 U-CYTECH
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA ASSAY KIT IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY SOURCE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA INFECTIOUS DISEASE IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA DIAGNOSTIC APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA RESEARCH APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA ASSAY KIT IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY SOURCE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA INFECTIOUS DISEASE IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA DIAGNOSTIC APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA RESEARCH APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISTRIBUTION, 2019-2028 (USD MILLION)
TABLE 22 U.S. ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 23 U.S. ASSAY KIT IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 24 U.S. ELISPOT AND FLUOROSPOT ASSAY MARKET, BY SOURCE, 2019-2028 (USD MILLION)
TABLE 25 U.S. ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 26 U.S. INFECTIOUS DISEASE IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 27 U.S. ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 28 U.S. DIAGNOSTIC APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 29 U.S. RESEARCH APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 30 U.S. ELISPOT AND FLUOROSPOT ASSAY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 U.S. ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISTRIBUTION, 2019-2028 (USD MILLION)
TABLE 32 CANADA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 33 CANADA ASSAY KIT IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 34 CANADA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY SOURCE, 2019-2028 (USD MILLION)
TABLE 35 CANADA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 36 CANADA INFECTIOUS DISEASE IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 37 CANADA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 38 CANADA DIAGNOSTIC APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 CANADA RESEARCH APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 40 CANADA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 CANADA ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISTRIBUTION, 2019-2028 (USD MILLION)
TABLE 42 MEXICO ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 43 MEXICO ASSAY KIT IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 44 MEXICO ELISPOT AND FLUOROSPOT ASSAY MARKET, BY SOURCE, 2019-2028 (USD MILLION)
TABLE 45 MEXICO ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 46 MEXICO INFECTIOUS DISEASE IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 47 MEXICO ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 48 MEXICO DIAGNOSTIC APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 49 MEXICO RESEARCH APPLICATION IN ELISPOT AND FLUOROSPOT ASSAY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 MEXICO ELISPOT AND FLUOROSPOT ASSAY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 51 MEXICO ELISPOT AND FLUOROSPOT ASSAY MARKET, BY DISTRIBUTION, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: VENDOR SHARE SECONDARY SOURCES
FIGURE 10 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: SEGMENTATION
FIGURE 11 INCREASED INCIDENCE OF CHRONIC DISEASES AND SURGE IN AWARENESS ABOUT THE TIMELY DIAGNOSIS OF THE DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 ASSAY KITS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET
FIGURE 14 PREVALENCE OF CHRONIC DISEASES DURING THE COVID-19 PANDEMIC
FIGURE 15 GLOBAL INCIDENCE OF KAWASAKI SYNDROME PER 100,000 CHILDREN UNDER 5 YEARS OF AGE
FIGURE 16 INCIDENCE OF CANCER, WHICH INCREASES WITH AGE
FIGURE 17 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY PRODUCT TYPE, 2020
FIGURE 18 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY PRODUCT TYPE, 2019-2028 (USD MILLION)
FIGURE 19 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 20 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY SOURCE, 2020
FIGURE 22 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY SOURCE, 2019-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY SOURCE, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISEASE, 2020
FIGURE 26 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISEASE, 2019-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISEASE, CAGR (2021-2028)
FIGURE 28 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY APPLICATION, 2020
FIGURE 30 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY END USER, 2020
FIGURE 34 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY END USER, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 38 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 39 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 40 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: SNAPSHOT (2020)
FIGURE 42 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY COUNTRY (2020)
FIGURE 43 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 44 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 45 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 46 NORTH AMERICA ELISPOT AND FLUOROSPOT ASSAY MARKET: COMPANY SHARE 2020 (%)
